Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13424894 | 0.88 | — | — | |
| SCHEMBL13424897 | 0.88 | — | — | |
| SCHEMBL2231452 | 0.88 | — | — | |
| SCHEMBL3719558 | 0.87 | TSHR (0.40) | TSHRSMN1; SMN2ALDH1A1MEN1USP2 | |
| SCHEMBL7771242 | 0.86 | THRB (0.46) | TSHRSMN1; SMN2ALDH1A1MEN1USP2 | |
| SCHEMBL15641242 | 0.85 | SMN1; SMN2 (0.36) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL15641252 | 0.85 | TSHR (0.36) | TSHRSMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL3685107 | 0.84 | — | — | |
| SCHEMBL7777469 | 0.84 | — | — | |
| SCHEMBL1290407 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260038861-A1 | ANOLYTES COMPRISING ALKANOLAMINE-BASED LIGANDS FOR REDOX FLOW BATTERY SYSTEMS | BATTELLE MEMORIAL INSTITUTE (US) | 2026-02-05 | — | — | US | disclosed |
| US-11166899-B2 | Composition for external application containing a ceramide, a derivative thereof and an extract of Hibisci cortex | AMOREPACIFIC CORPORATION (KR) | 2021-11-09 | — | — | US | disclosed |
| US-20210113712-A1 | METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS | LINXIS B V (NL) | 2021-04-22 | — | — | US | disclosed |
| US-20210113712-A1 | METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS | LINXIS B V (NL) | 2021-04-22 | — | — | US | disclosed |
| WO-2021060947-A2 | NOVEL SYNTHESIS METHOD OF PSEUDOCERAMIDE, AND INTERMEDIATES THEREOF | 대봉엘에스 주식회사 | 2021-04-01 | — | — | WO | disclosed |
| US-20200345862-A1 | TRANSITION METAL-BASED FUNCTIONAL MOIETIES FOR PREPARING CELL TARGETING CONJUGATES | LINXIS B V (NL) | 2020-11-05 | — | — | US | disclosed |
| US-20200345862-A1 | TRANSITION METAL-BASED FUNCTIONAL MOIETIES FOR PREPARING CELL TARGETING CONJUGATES | LINXIS B V (NL) | 2020-11-05 | — | — | US | disclosed |
| EP-3727464-A1 | METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS | LinXis B.V. (NL) | 2020-10-28 | — | — | EP | disclosed |
| US-20200179260-A1 | COMPOSITION FOR EXTERNAL APPLICATION CONTAINING A CERAMIDE, A DERIVATIVE THEREOF AND AN EXTRACT OF HIBISCI CORTEX | AMOREPACIFIC CORPORATION (KR) | 2020-06-11 | — | — | US | disclosed |
| US-9399192-B2 | Carbon dioxide absorber and carbon dioxide separation/recovery method using the absorber | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2016-07-26 | — | — | US | disclosed |
| US-20140127119-A1 | CARBON DIOXIDE ABSORBER AND CARBON DIOXIDE SEPARATION/RECOVERY METHOD USING THE ABSORBER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2014-05-08 | — | — | US | disclosed |
| US-20140127119-A1 | CARBON DIOXIDE ABSORBER AND CARBON DIOXIDE SEPARATION/RECOVERY METHOD USING THE ABSORBER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2014-05-08 | — | — | US | disclosed |
| EP-2719439-A1 | CARBON-DIOXIDE ABSORBER AND CARBON-DIOXIDE SEPARATION/RECOVERY METHOD USING SAID ABSORBER | Asahi Kasei Kabushiki Kaisha (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| US-6521662-B2 | For prevention of skin aging and damage caused by detergents which remove the lipids essential for the barrier function | PACIFIC CORPORATION (KR) | 2003-02-18 | — | — | US | disclosed |
| US-20010056083-A1 | Ceramide-like compounds having antioxidant property and a method for preparation thereof, and a cosmetic composition containing the same | AMOREPACIFIC CORPORATION (KR) | 2001-12-27 | — | — | US | disclosed |
| US-6060612-A | SKIN CARE COSMETIC | PACIFIC CORPORATION (KR) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166899-B2 | Composition for external application containing a ceramide, a derivative thereof and an extract of Hibisci cortex | CERT1, CERS2, SGMS1 | TSHR 4858/4885SMN1; SMN2 1478/4885ALDH1A1 3828/4885 |
| US-20260038861-A1 | ANOLYTES COMPRISING ALKANOLAMINE-BASED LIGANDS FOR REDOX FLOW BATTERY SYSTEMS | HAO2, ANO2, HRH4 | TSHR 1182/4885SMN1; SMN2 4055/4885ALDH1A1 756/4885 |
| US-20010056083-A1 | Ceramide-like compounds having antioxidant property and a method for preparation thereof, and a cosmetic composition containing the same | SGMS1, CERS2, SGMS2 | TSHR 4730/4885SMN1; SMN2 560/4885ALDH1A1 637/4885 |
| US-20210113712-A1 | METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS | CD47, EPCAM, CD44 | TSHR 2348/4885SMN1; SMN2 1447/4885ALDH1A1 1027/4885 |
| US-20200345862-A1 | TRANSITION METAL-BASED FUNCTIONAL MOIETIES FOR PREPARING CELL TARGETING CONJUGATES | CD2, CD47, EPCAM | TSHR 1313/4885SMN1; SMN2 2364/4885ALDH1A1 919/4885 |
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | TSHR 6/4885SMN1; SMN2 4013/4885ALDH1A1 2186/4885 |
| US-20200179260-A1 | COMPOSITION FOR EXTERNAL APPLICATION CONTAINING A CERAMIDE, A DERIVATIVE THEREOF AND AN EXTRACT OF HIBISCI CORTEX | CERT1, CERS2, SGMS1 | TSHR 4858/4885SMN1; SMN2 1478/4885ALDH1A1 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.